Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Non-Current Deferred Tax Liability (2022 - 2025)

InMed Pharmaceuticals has reported Non-Current Deferred Tax Liability over the past 3 years, most recently at $20000.0 for Q2 2025.

  • For Q2 2025, Non-Current Deferred Tax Liability changed N/A year-over-year to $20000.0; the TTM value through Jun 2025 reached $20000.0, changed N/A, while the annual FY2025 figure was $20000.0, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability for Q2 2025 was $20000.0 at InMed Pharmaceuticals, down from $211266.0 in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $211266.0 in Q2 2023 and troughed at $20000.0 in Q2 2025.
  • A 3-year average of $101024.0 and a median of $71806.0 in 2022 define the central range for Non-Current Deferred Tax Liability.
  • On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 194.22% in 2023 and fell as far as 194.22% in 2023.
  • Year by year, Non-Current Deferred Tax Liability stood at $71806.0 in 2022, then soared by 194.22% to $211266.0 in 2023, then tumbled by 90.53% to $20000.0 in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for INM at $20000.0 in Q2 2025, $211266.0 in Q2 2023, and $71806.0 in Q2 2022.